Food News and Research

RSS

Is it safe for SARS-CoV-2 positive mothers to breastfeed?

Even as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus continues to cause thousands of cases every day, with many deaths, life continues to move on regardless. Births occur as usual, and in many countries, mothers prefer to breastfeed their babies, at least for the first few months of life.

2 Jun 2020

Study reveals how a fat cell's immune response worsens obesity

When obesity occurs, a person's own fat cells can set off a complex inflammatory chain reaction that can further disrupt metabolism and weaken immune response--potentially placing people at higher risk of poor outcomes from a variety of diseases and infections, including COVID-19.

2 Jun 2020

Could the next pandemic be 100 times worse than COVID-19?

As the world tries to cope with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease (COVID-19), Dr. Michael Herschel Greger has claimed that worse could be yet to come. The American nutrition expert has claimed in his latest book that the next pandemic could be due to virus emanating from poultry farms.

2 Jun 2020

Data provides a baseline understanding of the eating habits of older adults before COVID-19

Most people in their 50s and older were capable home cooks just before COVID-19 struck America, but only 5% had ordered groceries online, according to a new national poll.

2 Jun 2020

Towards effective protection of water resources and human health

The covid-19 pandemic has shown us that public health can be endangered by "hidden enemies" like viruses that cannot be detected by our senses.

2 Jun 2020

Hiring a diverse army to track COVID-19 amid reopening

As a contact tracer, Teresa Ayala-Castillo is sometimes asked whether herbal teas and Vicks VapoRub can treat COVID-19. These therapies aren't exactly official health guidance, but Ayala-Castillo isn't fazed. She listens and then suggests other ideas — like getting rest and drinking plenty of fluids.

2 Jun 2020

Crucial ingredient from University of Kansas included in authorized COVID-19 drug

When the Food and Drug Administration issued an emergency-use authorization for the investigational pharmaceutical remdesivir to treat COVID-19 on May 1, in part it was due to pioneering work performed by pharmaceutical chemists at the University of Kansas School of Pharmacy in 1990.

1 Jun 2020

COVID-19 negatively impacts people with eating disorders

A study analyzing the early impact that coronavirus disease 2019 (COVID-19) is having on people with eating disorders has identified areas where their treatment needs could be better addressed.

1 Jun 2020

Dogs could help monitor how environmental chemicals impact human health

Man's best friend may also be man's best bet for figuring out how environmental chemicals could impact our health.

1 Jun 2020

WVU researchers explore woody biomass for protection against COVID-19

As healthcare facilities grapple with personal protective equipment shortages, West Virginia University researchers are going against the grain to help with an earthy, unorthodox resource: wood.

1 Jun 2020

Studies call for reforms to improve nutritional programs in HIV care settings

HIV management in developing countries varies with socioeconomic and structural circumstances, with two Flinders University studies finding examples of key ways to close the gap for those worst affected in developing countries.

1 Jun 2020

‘Why do we always get hit first?’ Proposed budget cuts target vulnerable Californians

Shirley Madden, 83, relies on a caregiver and her two grown daughters to remain living at home — and not in a nursing home.

1 Jun 2020

Expert warns that UK employers may face legal action over COVID-19 exposure

Employers across the UK could face legal action from employees who return to work and contract the COVID-19 virus, a leading health and safety expert has warned.

1 Jun 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

The ‘eureka moment’ of rapid COVID-19 test inventor

The inventor of a ground-breaking COVID-19 test described his ‘eureka moment’ when he realised he could adapt existing tech to create a rapid virus test.

30 May 2020

Assessing treatment for acute chloroquine poisoning

Research by Bangor University’s Professor Dyfrig Hughes has provided important evidence on the safety of treatments that are being tested for use in COVID-19.

30 May 2020

Expert offers COVID-19 guidance for patients with COPD

Chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, is a chronic lung disease that makes it hard to breathe. The disease affects millions of Americans and is the fourth leading cause of disease-related death in the U.S. People with COPD have a higher risk of more severe illness from COVID-19 due to their existing lung problems.

30 May 2020

UMSOM scientists develop experimental rapid diagnostic test for COVID-19

Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes.

29 May 2020

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology Annual Meeting ASCO20 Virtual Meeting (Abstract 9556 - Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020